
"This is the pre-peer reviewed version of the following article: Mondal, S et al (2019) Angew Chem Int Ed Engl 10.1002/ange.201906334, which has been published in final form at <https://onlinelibrary.wiley.com/doi/abs/10.1002/ange.201906334?af=R>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions."

Halogen Bonding Increases the Potency and Isozyme-selectivity of Protein Arginine Deiminase 1 Inhibitors

Santanu Mondal,^[a] Xuefeng Gong,^[b] Xiaoqian Zhang,^[b] Ari J. Salinger,^{[a][c]} Li Zheng,^[a] Sudeshna Sen,^[a] Eranthie Weerapana,^[c] Xuesen Zhang,^[b] and Paul R. Thompson*^[a]

[a] Dr. S. Mondal, Dr. A. J. Salinger, Dr. L. Zheng, Dr. S. Sen, Prof. Dr. P. R. Thompson

Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation street, Worcester, MA 01605, USA, E-mail: paul.thompson@umassmed.edu

[b] X. Gong, X. Zhang, Dr. X. Zhang, State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 211166, China

[c] Dr. A. J. Salinger, Prof. Dr. E. Weerapana, Department of Chemistry, Boston College, Chestnut Hill, MA 02467, USA

Abstract: Protein Arginine Deiminases (PADs) hydrolyze the side chain of arginine to form citrulline. Aberrant PAD activity is associated with rheumatoid arthritis, multiple sclerosis, lupus, and certain cancers. These pathologies established the PADs as therapeutic targets and multiple PAD inhibitors are known. Herein, we describe the first highly potent PAD1-selective inhibitors (**1** and **19**). Detailed structure-activity relationships indicate that their potency and selectivity is due to the formation of a halogen bond with PAD1. Importantly, these inhibitors inhibit histone H3 citrullination in HEK293TPAD1 cells and mouse zygotes with excellent potency. Based on this scaffold, we also developed a PAD1-selective activity-based probe that shows remarkable cellular efficacy and proteome selectivity. Based on their potency and selectivity we expect that **1** and **19** will be widely used chemical tools to understand PAD1 biology.

Citrullination, a post-translational modification (PTM) of arginine, plays pivotal roles in several processes, including the epigenetic regulation of gene expression, neutrophil extracellular trap (NET)-formation and DNA-damage induced apoptosis.^[1] Protein citrullination is catalyzed by the protein arginine deiminases or PADs (Figure 1A). Of the five PAD isozymes (PAD1, 2, 3, 4 and 6), only four (PADs1-4) are catalytically active. PAD activity is tightly regulated by Ca^{2+} and PADs contain 4 (PAD1), 5 (PAD3, 4) or 6 (PAD2) Ca^{2+} -binding sites.^[2] Ca^{2+} -binding reorients key catalytic residues into catalytically competent positions. Catalysis is mediated by a nucleophilic cysteine (C645 in PAD1, 4; C647 in PAD2; C646 in PAD3), a histidine (H471), and two aspartates (D350 and D473) that properly orient the substrate guanidinium group for nucleophilic attack by the cysteine.^[1b, 1d] In addition to their important physiological roles, aberrant protein citrullination leads to several autoimmune diseases (e.g., rheumatoid arthritis, lupus, and multiple sclerosis) as well as certain cancers. These disease links have established multiple PADs as promising therapeutic targets.^[1b, 1d]

Cl-amidine and BB-Cl-amidine are two widely used pan-PAD inhibitors that possess a chloroacetamide warhead that




Figure 1. (A) Conversion of peptidyl-arginine to peptidyl-citrulline by the protein arginine deiminases (PADs). (B) Chemical structures and potencies of PAD inhibitors. (C) Crystal structure of the PAD4-o-Cl-amidine complex (PDB: 3B1U).

covalently modifies the active site cysteine (Figure 1B).^[3] Although these inhibitors inhibit PADs1-4 similarly, BB-Cl-amidine shows superior efficacy in cells and animal models of disease owing to its

higher cell permeability and metabolic stability.^[3a] Interestingly, *o*-Cl-amidine, with a carboxylate substitution on the Cl-amidine scaffold, exhibits superior potencies for PAD inhibition (Figure 1B).^[4] A structure of PAD4 bound to *o*-F-amidine, a fluoroacetamide-containing analogue, indicates that the carboxylate hydrogen bonds with W347 (universally conserved amongst the PADs) and makes a water-mediated hydrogen bond with Q346 (Figure 1C). However, *o*-Cl-amidine exhibits poor cellular efficacy, likely due to the negatively charged carboxylate that limits cell permeability.

Recently, the use of halogens in medicinal chemistry has gained significant interest due to their high lipophilicity which boosts cell permeability.^[5] Expecting this approach to increase the cell permeability of PAD inhibitors, we synthesized **1** with a 2-hydroxyl (which we hypothesized might form a hydrogen bond with W347), 3,5-diiodo substitutions in the N-terminal phenyl ring (to enhance permeability), and a C-terminal benzimidazole substitution (as in BB-Cl-amidine) (Figure 2A). Notably, this compound contains the less-reactive fluoroacetamide warhead, which has less off-target toxicity.^[6] Remarkably, **1** exhibits 74-fold selectivity for PAD1 over the other PADs with a $k_{\text{inact}}/K_{\text{I}}$ value of $10,400 \pm 2,380 \text{ M}^{-1}\text{min}^{-1}$ (Figure 2B). To our knowledge, this is the first example of a highly selective fluoroacetamide-containing PAD1 inhibitor. By contrast, compound **2**, which contains a chloroacetamide warhead, is only 19-fold selective for PAD1 (Figure 2B and Table S1). The loss of selectivity observed with this warhead is consistent with previous studies showing that the fluoroacetamide warhead can impart a higher degree of selectivity.^[7]




Figure 2. (A) Chemical structures of **1-22**. (B) Potency heat-map of fluoroacetamidine-containing compounds for PADs1-4. The kinetics of inhibition of PADs by **1-22** are given in Figures S1-4. (C) Chemical structure of RFA and inhibition of RFA labelling of PAD1 by compounds **1**, **11**, **13** and **7**. I, inhibitor; F, fluorograph; C, coomassie stain.

To investigate the origin of its potency and PAD1 selectivity, we established a structure-activity relationship (SAR) for **1**. Since fluoroacetamidine-containing compounds afford better isozyme-selectivity, we only discuss these compounds in our analysis. The potency of the chloroacetamidine-containing compounds are, however, provided (Tables S1-S2) and they follow similar trends. Briefly, **3** and **5**, which replace the 2-hydroxyl with a methoxy and hydrogen substitution, respectively, exhibit similar potency for PAD1 but a significant loss in selectivity (Figure 2B and Table S1). By contrast, **7**, which lacks the iodo groups at 3- and 5-positions, shows an 87-fold drop in potency for PAD1 and a remarkable loss in selectivity. In fact, **7** is 21-fold selective for PAD4 (Figure 2B and Table S1). These results indicate that the 2-hydroxyl group is important for PAD1 selectivity, while the iodo groups are responsible for both potency and PAD1 selectivity. Given this data, we initially hypothesized that the iodo groups contribute to potency and selectivity *via* the formation of favourable hydrophobic interactions

with PAD1. However, **9**, which replaces the iodo groups with hydrophobic and isosteric isopropyl groups, exhibits almost identical activity as **7**, suggesting that the iodo groups may be forming a halogen bond.

Owing to their anisotropic charge distribution, halogens in organic halides contain a significant amount of positive electrostatic potential (σ -hole) along the C-X (X = halogen) axis, and this potential increases in the order, Cl<Br<I. Therefore, in the presence of a suitable electron donor (D, often the backbone carbonyl or polar side chains of proteins), halogens act as an electrophile to form a halogen bond (D \cdots X-C).^[5c, 8] There are numerous examples where halogen bonds increase the affinity of small molecules for their proteins targets.^[5a, 5c] For example, an iodophenol-based p53-cancer mutant (Y220C) stabilizer forms a halogen bond with the backbone carbonyl of L145.^[9]

To validate the possible formation of halogen bonds between compound **1** and PAD1, we synthesized **11-14** with bromo- and chloro substitutions at the 3- and 5-positions. Since the positive potential on halogens decreases in the order: I>Br>Cl, the strength of a halogen bond follows the same order. Therefore, if a halogen bond is present, potency should decrease in that order. In fact, we observed a gradual decrease in both potency and selectivity upon replacement of the iodo groups. For example, **11** is 3-fold less potent than **1** and exhibits only 25-fold PAD1 selectivity, whereas **13** is 8-fold less potent than **1** and exhibits only 10-fold selectivity for PAD1 (Figure 2B and Table S1). Furthermore, the k_{inact} and K_{I} values for **1**, **11** and **13** reveal that while these compounds share similar inactivation rates (k_{inact}), there is a gradual decrease in binding affinity, as measured by an increase in K_{I} , as one goes from **1** (12.5 μM) to **11** (54.8 μM) to **13** (124.5 μM) (Table S2). These observations clearly indicate that the potency and selectivity of **1** originates from the iodo groups that form halogen bonds with PAD1. Although different halogens are also expected to alter the $\text{p}K_{\text{a}}$ of the 2-hydroxyl, and thereby enhance hydrogen bond formation of this group to W347, the potency of the inhibitor is expected to increase as the electronegativity of the halogen atoms increase.

We further confirmed the halogen-dependent change in potency with an activity-based protein profiling (ABPP) assay that uses the PAD-targeted probe, rhodamine-conjugated F-amidine (RFA, Figure

2C).^[10] RFA enables the covalent modification and fluorescent labelling of PADs. In the presence of a PAD inhibitor, however, RFA labelling is inhibited.^[11] Using this assay, **1** inhibited RFA labelling of PAD1 with an IC₅₀ of 18 μM (Figure 2C). Consistent with the $k_{\text{inact}}/K_{\text{I}}$ data, compounds **11**, **13** and **7** with bromo-, chloro- and hydrogen substitutions at the 3- and 5-positions, respectively, exhibit a gradual decrease in the potency (Figure 2C). Similar results were obtained with the chloroacetamide-containing compounds **2**, **12**, **14** and **8** (Figure S5).

Having established their importance, we next questioned whether both iodo groups contribute to potency and selectivity. Although a structure of PAD1 in complex with **1** would definitively address this issue, several attempts to crystallize this complex were unsuccessful. Therefore, we synthesized **15-18** which contain an iodo group at either the 3- or 5-position (Figure 2A). Notably, **15** and **17** are 7- and 35-fold less potent than the parent compound **1**. Furthermore, **15** and **17** are only 13- and 3-fold selective for PAD1 (Figure 2B and Table S1). These results indicate that both iodines are important for potency and PAD1 selectivity. Moreover the data indicate that the 3-iodine places the iodine at the 5-position in a suitable position to form a halogen bond. Since electron withdrawing substituents increase the halogen bond strength by increasing the positive potential on halogen, we synthesized **19** and **20** which contain a fluoro substitution in the parent scaffold (Figure 2A). **19** exhibited improved potency ($k_{\text{inact}}/K_{\text{I}} = 13250 \pm 2870 \text{ M}^{-1}\text{min}^{-1}$) and was 44-fold selective for PAD1 (Figure 2B and Table S1).

We next evaluated cellular potency in PAD1-overexpressing HEK293TPAD1 cells (see Figure S6 for PAD1 expression). As previously reported in mouse embryos,^[12] we found that PAD1 citrullinates histone H3 at the 2, 8 and 17 positions *in vitro* and in HEK293TPAD1 cells in the presence of calcium (Figure S7). Gratifyingly, **1** and **19** inhibit histone H3 citrullination in a dose-dependent manner with EC₅₀ values of 14.5 and 31.8 μM, respectively (Figure 3A-C). In contrast to the 6-7-fold higher




Figure 3. (A-C) Inhibition of histone H3 citrullination in HEK293TPAD1 cells by **1**, **7**, **11**, **13** and **19**. **1**, inhibitor; NA, Not applicable. (D) Inhibition of development of pronuclear mouse zygotes into blastocysts by **1** and **19**. Embryo development was monitored by light microscopy. C, DMSO-treated control. (E) Confocal microscopy of mouse embryos at the 4-cell stage, indicating the inhibition of histone H3 citrullination by **1** and **19**. anti-Histone H3Cit2/8/17 antibody and DAPI were used for immunofluorescence staining of citrullinated histone H3 and DNA, respectively. C refers to control.

in vitro potency, chloroacetamide-containing compounds **2** and **20** exhibit only 1.3-2-fold higher activity in cells compared to **1** and **19** (Figure S8). These results indicate that despite having a lower *in vitro* potency, fluoroacetamide-containing compounds exhibit similar cellular activity to chloroacetamide-containing compounds, likely due to their lower off-target toxicity. Interestingly, the cellular activities of **1**, **7**, **11** and **13** for the inhibition of histone H3 citrullination in HEK293TPAD1 cells also follow the order **1**>**11**>**13**>**7** (Figures 3A-C), paralleling their *in vitro* potencies (Figures 1B). We do recognize, however, that this trend may also be due to a combination of potency and cell permeability as the lipophilicity of these compounds follows the same order (see log P values in Table S3). Notably, the

Efficacy Index (the ratio of cytotoxicity to EC₅₀) of **1** and **19** are 17 and 10, respectively, indicating that these compounds inhibit cellular PAD1 without causing significant toxicity (Figure 3C and S9).

PAD1 is the predominant nuclear PAD in early embryos and PAD1-catalyzed histone H3 citrullination is essential for early embryo development.^[12] Depletion of PAD1 in mouse zygotes does not affect oocyte maturation or pronuclear formation but dramatically arrests early embryo development at the 4-8-cell stage. Encouraged by the inhibition of histone H3 citrullination in HEK293TPAD1 cells, we evaluated **1** and **19** in pronuclear (PN) zygotes and showed that these compounds dramatically arrest embryo development at the morula stage. By contrast, 87% of control zygotes progressed to the blastocyst stage (Figure 3D). Notably, the arrest in embryo development correlates strongly with the inhibition of histone H3 citrullination by **1** and **19** as revealed by immunofluorescence (Figures 3E and S10). These observations show that **1** and **19** inhibit endogenous levels of PAD1.

We also synthesized **21** and **22** (Figure 2A), which contain an alkyne handle that can be conjugated with fluorescent (TAMRA)- or biotin-containing reporter tags using the copper-catalyzed alkyne-azide cycloaddition (CuAAC) reaction for ABPP-based applications. Similar to the parent compounds, **21** and **22** exhibit almost 34- and 9-fold selectivity for PAD1 over the other PADs (Figure 2B and Table S1). **21** dose-dependently labels recombinant PAD1 with a limit of detection (LOD) of 4.3 pmol when using TAMRA-N₃ as the reporter tag (Figure 4A, see top and bottom for dose-dependence and LOD, respectively). Similar results were obtained with **22** (Figure S11). Fluorescence intensities, normalized against the Coomassie stain intensities, for the labelling of PADs 1-4 by **21** and **22** indicate that **21** exhibits significant selectivity for PAD1, whereas **22** is less selective (Figure 4B). Therefore, we used **21** to label PAD1 in HEK293TPAD1 cells (Figure 4C). Gratifyingly, **21** labels PAD1 in these cells in a dose- and time-dependent manner (Figures 4D and S12). The cellular LOD is an impressive 72 pmol (Figure S12B). Encouraged by the selective labelling of PAD1, we used **21** to develop a target engagement assay to evaluate the cellular potency of PAD1 inhibitors. For this application, we tested whether compound **1** could block labelling of PAD1 by **21**. As expected, compound **1** dose-dependently inhibits the labelling

of PAD1 by **21** in HEK293TPAD1 cells (Figure 4E) with an EC₅₀ of 12.7 μM, which is similar to that obtained for the inhibition of histone H3 citrullination (Figure 3C). We also coupled a **21**-labeled HEK293TPAD1 proteome to Biotin-N₃ and selectively captured the biotinylated proteins on streptavidin-agarose beads followed by an on-bead digestion of the captured proteins with trypsin (Figures 4C and S13). Reductive methylation (ReDiMe) was then performed on the trypsin digest with heavy (for the **21**-treated samples) or light (for control samples) formaldehyde and sodium cyanoborohydride. Subsequent proteomic analysis afforded the enrichment ratio of the proteins that are covalently modified by **21**. Impressively, PAD1 was the main protein isolated by **21** in HEK293TPAD1 cells, indicating the remarkable proteome-wide selectivity of this molecular scaffold. (Figure 4F).

In summary, we developed iodinated chemical probes with excellent potency and PAD1 selectivity. The high potency and selectivity arises mainly from the iodo groups, which form halogen bonding interactions with PAD1. These PAD1 inhibitors inhibit histone H3 citrullination in HEK293TPAD1 cells and mouse embryos with excellent efficacy. To the best of our knowledge, this is the first demonstration of a potent PAD1 inhibitor with a fluoroacetamidine warhead and the potential use of halogens to increase the potency and isozyme-selectivity of PAD inhibitors.




Figure 4. (A) Dose-response (top) and limit of detection (bottom) studies of labelling of recombinant PAD1 by **21**. F, fluorograph; C, coomassie stain. (B) Selectivity of labelling of PADs1-4 by **21** and **22**. (C) Schematic representation of labelling of PAD1 by **21** in HEK293TPAD1 cells. (D) Dose-response of labelling of PAD1 in HEK293TPAD1 cells by **21**. An immunoblot using anti-FLAG antibody is used as a loading control. (E) Target engagement assay in HEK293TPAD1 cells using **21** (5 μ M) and increasing concentrations of **1**. (F) Selective enrichment of PAD1 in HEK293TPAD1 cells by **21**. Enrichment ratio is determined from the proportion of heavy and light formaldehyde labelling of probe-treated and control samples, respectively.

Experimental Section

Synthesis and characterization of inhibitors and probes (Figures S14-S57), *in vitro* PAD inactivation, cell-based assays, and the labelling of recombinant and cellular PAD1 are discussed in supporting information.

Conflict of Interest

P.R.T. founded Padlock Therapeutics and is entitled to payments from Bristol Myers Squibb if certain milestones are met. P.R.T. is a consultant for Celgene and Disarm Therapeutics. We are filing a patent based on these results.

Keywords: Activity-based protein profiling (ABPP) • Covalent protein modification • Halogen bonding • Histone citrullination • Protein arginine deiminase (PAD)

[1] a) V. Brinkmann, U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D. S. Weiss, Y. Weinrauch, A. Zychlinsky, *Science* **2004**, *303*, 1532-1535; b) J. Fuhrmann, K. W. Clancy, P. R. Thompson, *Chem. Rev.* **2015**, *115*, 5413-5461; c) E. F. Kenny, A. Herzig, R. Kruger, A. Muth, S. Mondal, P. R.

-
- Thompson, V. Brinkmann, H. V. Bernuth, A. Zychlinsky, *Elife* **2017**, *6*; d) S. Mondal, P. R. Thompson, *Acc. Chem. Res.* **2019**, *52*, 818-832.
- [2] a) K. Arita, H. Hashimoto, T. Shimizu, K. Nakashima, M. Yamada, M. Sato, *Nat. Struct. Mol. Biol.* **2004**, *11*, 777-783; b) S. Saijo, A. Nagai, S. Kinjo, R. Mashimo, M. Akimoto, K. Kizawa, T. Yabe-Wada, N. Shimizu, H. Takahara, M. Unno, *J. Mol. Biol.* **2016**, *428*, 3058-3073; c) D. J. Slade, P. Fang, C. J. Dreyton, Y. Zhang, J. Fuhrmann, D. Rempel, B. D. Bax, S. A. Coonrod, H. D. Lewis, M. Guo, M. L. Gross, P. R. Thompson, *ACS Chem. Biol.* **2015**, *10*, 1043-1053.
- [3] a) J. S. Knight, V. Subramanian, A. A. O'Dell, S. Yalavarthi, W. Zhao, C. K. Smith, J. B. Hodgins, P. R. Thompson, M. J. Kaplan, *Ann. Rheum. Dis.* **2015**, *74*, 2199-2206; b) Y. Luo, B. Knuckley, Y. H. Lee, M. R. Stallcup, P. R. Thompson, *J. Am. Chem. Soc.* **2006**, *128*, 1092-1093.
- [4] C. P. Causey, J. E. Jones, J. L. Slack, D. Kamei, L. E. Jones, V. Subramanian, B. Knuckley, P. Ebrahimi, A. A. Chumanevich, Y. Luo, H. Hashimoto, M. Sato, L. J. Hofseth, P. R. Thompson, *J. Med. Chem.* **2011**, *54*, 6919-6935.
- [5] a) L. Mendez, G. Henriquez, S. Sirimulla, M. Narayan, *Molecules* **2017**, *22*; b) H. Ungati, V. Govindaraj, G. Mugesh, *Angew. Chem. Int. Ed. Engl.* **2018**, *57*, 8989-8993; c) R. Wilcken, M. O. Zimmermann, A. Lange, A. C. Joerger, F. M. Boeckler, *J. Med. Chem.* **2013**, *56*, 1363-1388.
- [6] V. V. Nemmara, V. Subramanian, A. Muth, S. Mondal, A. J. Salinger, A. J. Maurais, R. Tilvawala, E. Weerapana, P. R. Thompson, *ACS Chem. Biol.* **2018**, *13*, 712-722.
- [7] A. Muth, V. Subramanian, E. Beaumont, M. Nagar, P. Kerry, P. McEwan, H. Srinath, K. Clancy, S. Parelkar, P. R. Thompson, *J. Med. Chem.* **2017**, *60*, 3198-3211.
- [8] a) P. Metrangolo, F. Meyer, T. Pilati, G. Resnati, G. Terraneo, *Angew. Chem. Int. Ed. Engl.* **2008**, *47*, 6114-6127; b) S. Mondal, D. Manna, G. Mugesh, *Angew. Chem. Int. Ed. Engl.* **2015**, *54*, 9298-9302; c) S. Mondal, G. Mugesh, *Chem. Eur. J.* **2014**, *20*, 11120-11128; d) S. Mondal, G. Mugesh, *Angew. Chem. Int. Ed. Engl.* **2015**, *54*, 10833-10837; e) S. Mondal, G. Mugesh, *Cryst. Growth Des.* **2016**, *16*, 5896-5906; f) S. Mondal, K. Raja, U. Schweizer, G. Mugesh, *Angew. Chem. Int. Ed. Engl.* **2016**, *55*, 7606-7630.

-
- [9] R. Wilcken, X. Liu, M. O. Zimmermann, T. J. Rutherford, A. R. Fersht, A. C. Joerger, F. M. Boeckler, *J. Am. Chem. Soc.* **2012**, *134*, 6810-6818.
- [10] Y. Luo, B. Knuckley, M. Bhatia, P. J. Pellechia, P. R. Thompson, *J. Am. Chem. Soc.* **2006**, *128*, 14468-14469.
- [11] S. Mondal, S. S. Parelkar, M. Nagar, P. R. Thompson, *ACS Chem. Biol.* **2018**, *13*, 1057-1065.
- [12] X. Zhang, X. Liu, M. Zhang, T. Li, A. Muth, P. R. Thompson, S. A. Coonrod, *Sci. Rep.* **2016**, *6*, 38727.